Search results for "right ventricular dysfunction"

showing 10 items of 12 documents

The risk factor age in normotensive patients with pulmonary embolism: Effectiveness of age in predicting submassive pulmonary embolism, cardiac injur…

2015

Abstract Introduction Right ventricular dysfunction (RVD), submassive pulmonary embolism (PE), elevated systolic pulmonary artery pressure (sPAP), elevated cardiac troponin I (cTnI) and old age are well-known risk factors for poor outcome in acute normotensive PE. The aim of this analysis was to calculate age cut-off values to predict submassive PE, cardiac injury, RVD and elevated sPAP in normotensive PE patients. Methods Retrospective analysis of clinical, laboratory, radiological and echocardiographic data of normotensive PE patients (2006–2011) was performed. Receiver operating characteristic (ROC) curves and Youden indexes were used to test the effectiveness of using patients' ages at …

MaleAgingmedicine.medical_specialtyCardiac troponinVentricular Dysfunction RightBlood PressureBiochemistryRisk AssessmentEndocrinologyRisk FactorsInternal medicinemedicine.arteryGermanyTroponin IGeneticsmedicineHumansPulmonary Wedge PressureRisk factorMolecular BiologyAgedRetrospective StudiesReceiver operating characteristicbusiness.industryTroponin IAge FactorsCell Biologymedicine.diseasePrognosisThrombosisRight ventricular dysfunctionPulmonary embolismROC CurveEchocardiographyPulmonary arteryAcute DiseaseCardiologyFemalebusinessPulmonary EmbolismExperimental gerontology
researchProduct

Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review an…

2018

Abstract Aims Patients with acute pulmonary embolism (PE) classified as low risk by the Pulmonary Embolism Severity Index (PESI), its simplified version (sPESI), or the Hestia criteria may be considered for early discharge. We investigated whether the presence of right ventricular (RV) dysfunction may aggravate the early prognosis of these patients. Methods and results We did a systematic review and meta-analysis of studies including low-risk patients with acute PE to investigate the prognostic value of RV dysfunction. Diagnosis of RV dysfunction was based on echocardiography or computed tomography pulmonary angiography. In addition, we investigated the prognostic value of elevated troponin…

MaleComputed Tomography AngiographyVentricular Dysfunction Right030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineNatriuretic peptidePulmonary angiographyHospital MortalityRight ventricular dysfunctionAged 80 and overbiologyMortality rateHome treatmentMiddle AgedPrognosisTroponinPulmonary embolismEchocardiographyMeta-analysisAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtymedicine.drug_classFast Track Clinical ResearchRisk Assessment03 medical and health sciencesAnticoagulationInternal medicinemedicineHumansMortalityNatriuretic PeptidesRisk stratificationAgedbusiness.industryPulmonary embolismAnticoagulants030229 sport sciencesOdds ratiomedicine.diseaseTroponinConfidence intervalEditor's Choicebiology.proteinbusinessBiomarkersEuropean Heart Journal
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension

2009

Activation of the immune system is well established in patients with chronic heart failure (CHF) and impaired left ventricular function. High levels of pro-inflammatory cytokines are associated with a poor prognosis. Chronic thromboembolic pulmonary hypertension (CTEPH) frequently leads to impaired right ventricular function. It is not known whether such patients display chronic immune activation as well.We studied 49 patients with CTEPH (50±2 years, right ventricular ejection fraction [RVEF] 29±2%, left ventricular ejection fraction [LVEF] 51±3%, mean±SEM) and compared their results with 17 patients with CHF (71±2 years, LVEF 23±1%) and 34 age-matched control subjects (age 57±2 years). We …

Malemedicine.medical_specialtymedicine.drug_classHypertension PulmonaryVentricular Dysfunction RightInflammationImmune systemInternal medicinemedicineNatriuretic peptideHumanscardiovascular diseasesReceptorInflammationEjection fractionbusiness.industryMiddle Agedmedicine.diseaseRight ventricular dysfunctionHeart failurecardiovascular systemCardiologyFemaleTumor necrosis factor alphamedicine.symptomPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Impact of Right Ventricular Dysfunction on Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation

2021

OBJECTIVES This study sought to assess the impact of right ventricular dysfunction (RVD) as defined by impaired right ventricular-to-pulmonary artery (RV-PA) coupling, on survival after edge-to-edge transcatheter mitral valve repair (TMVR) for severe secondary mitral regurgitation (SMR). BACKGROUND Conflicting data exist regarding the benefit of TMVR in severe SMR. A possible explanation could be differences in RVD. METHODS Using data from the EuroSMR (European Registry on Outcomes in Secondary Mitral Regurgitation) registry, this study compared the characteristics and outcomes of SMR patients undergoing TMVR, according to their RV-PA coupling, assessed by tricuspid annular plane systolic e…

medicine.medical_specialtyAdverse outcomesVentricular Dysfunction Right030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicine.arterymedicineHumansRadiology Nuclear Medicine and imagingIn patientCardiac Surgical Procedures610 Medicine & healthMitral regurgitationbusiness.industryMitral Valve InsufficiencyRight ventricular dysfunctionTreatment Outcomemedicine.anatomical_structurePulmonary arteryCardiologyTranscatheter mitral valve repairCardiology and Cardiovascular MedicinebusinessArteryJACC: Cardiovascular Imaging
researchProduct

Elevated systolic pulmonary artery pressure for prediction of myocardial necrosis and right ventricular dysfunction in acute pulmonary embolism

2016

Kontext: Echokardiografie je v soucasnosti hlavni metodou pro vysetřeni dysfunkce prave komory (right ventricular dysfunction, RVD) u akutni plicni embolie (PE). Dysfunkce prave komory je sice spojena s nepřiznivou prognozou, dosud vsak nebyla přijata žadna obecně uznavana definice. Systolický tlak v plicnici (systolic pulmonary artery pressure, sPAP) větsinou neni soucasti kriterii RVD. Cilem nasi studie bylo zhodnotit možnost použiti sPAP v predikci nekrozy myokardu a RVD u akutni PE.Metody: Retrospektivně byly analyzovany udaje 182 pacientů s akutni PE. Pacienti s PE a hodnotami sPAP ≤ 30 mm Hg byli srovnavani s pacienty s PE a hodnotami sPAP > 30 mm Hg. Vztahy mezi sPAP na jedne straně …

medicine.medical_specialtyCardiac troponinmedicine.diagnostic_testbusiness.industryComputed tomographyV q scan030204 cardiovascular system & hematologymedicine.diseaseRight ventricular dysfunctionPulmonary embolism03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arteryPulmonary arteryRisk stratificationmedicineCardiology030212 general & internal medicineMyocardial necrosisCardiology and Cardiovascular MedicinebusinessCor et Vasa
researchProduct

Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis

2018

Aims Controversial reports exist in the literature regarding the prognostic role and therapeutic implications of syncope in patients with acute pulmonary embolism (PE). We conducted a systematic review and meta-analysis to investigate the association between syncope and short-term adverse outcomes, taking into account the presence or absence of haemodynamic compromise at acute PE presentation. Methods and results The literature search identified 1664 studies, 29 of which were included for a total of 21 956 patients with PE (n = 3706 with syncope). Syncope was associated with higher prevalence of haemodynamic instability [odds ratio (OR) 3.50; 95% confidence interval (CI) 2.67-4.58], as well…

medicine.medical_specialtyHemodynamicsBlood Pressure030204 cardiovascular system & hematologyGlobal HealthSyncopeRisk-stratification03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumans030212 general & internal medicineMortalityRight ventricular dysfunctionbiologybusiness.industryIncidence (epidemiology)IncidencePulmonary embolismSyncope (genus)Absolute risk reductionOdds ratiomedicine.diseasebiology.organism_classificationPrognosisConfidence interval3. Good healthPulmonary embolismSurvival RateEchocardiographyMeta-analysisAcute DiseasebusinessCardiology and Cardiovascular Medicine
researchProduct

Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15‐year prospective longitudinal trajectories in survivors

2020

Aims Systolic pulmonary artery pressure (SPAP), tricuspid annular plane systolic excursion (TAPSE), and TAPSE/SPAP ratio trajectories are not fully characterized in chronic heart failure (HF). We assessed very long-term longitudinal SPAP, TAPSE and TAPSE/SPAP trajectories in HF patients, and their dynamic changes in outcomes. Methods and results Prospective, consecutive, observational registry of real-life HF patients, performing echocardiography studies at baseline and according to a prospectively structured schedule after 1 year, and then every 2 years, up to 15 years. Pulmonary hypertension (PH) was defined as SPAP ≥40 mmHg; right ventricular dysfunction (RVD) was defined at TAPSE ≤16 mm…

medicine.medical_specialtyLong term follow upHypertension PulmonaryVentricular Dysfunction Right030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicine.arteryInternal medicinemedicineClinical endpointHumansIn patientProspective StudiesSurvivorsHeart Failurebusiness.industryPrognosismedicine.diseasePulmonary hypertensionRight ventricular dysfunctionstomatognathic diseasesHeart failurePulmonary arteryCohortVentricular Function RightCardiologyCardiology and Cardiovascular MedicinebusinessEuropean Journal of Heart Failure
researchProduct

Edoxaban for pulmonary embolism with right ventricular dysfunction

2016

medicine.medical_specialtyPyridinesbusiness.industryVentricular Dysfunction RightVenous ThromboembolismHematology030204 cardiovascular system & hematologymedicine.diseaseRight ventricular dysfunctionPulmonary embolismThiazoles03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningchemistryEdoxabanInternal medicinemedicineCardiologyHumans030212 general & internal medicinePulmonary EmbolismbusinessThe Lancet Haematology
researchProduct

Response to ‘Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonar…

2019

medicine.medical_specialtyRivaroxabanmedicine.diagnostic_testmedicine.drug_mechanism_of_actionbusiness.industryFactor Xa Inhibitormedicine.diseaseRight ventricular dysfunctionPulmonary embolismComputed tomographicAngiographyPulmonary angiographyMedicineIn patientRadiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct